Listen
INDUCTOS (dibotermin alfa), osteoinductive protein
SURGERY - Focus
Opinions on drugs -
Posted on
Jul 15 2015
Reason for request
Re-assessment of the actual benefit and the improvement in actual benefit
Low actual benefit and no clinical benefit demonstrated in tibia fractures and lumbar degenerative disc disease with anterior lumbar interbody fusion
- INDUCTOS has Marketing Authorisation in the treatment of tibia fractures and as a substitute for autogenous bone grafts in lumbar interbody fusion (See below).
- In the treatment of tibia fractures, the use of INDUCTOS is marginal The company was not able to perform the follow-up study requested in this indication in 2003.
- In the treatment of lumbar degenerative disc disease with anterior lumbar interbody fusion, its superiority compared with autogenous bone grafts has not been demonstrated with a rigorous methodology.
Clinical Benefit
| Low |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
